Philips Launches its First Clinical Product for Aiding Cognitive Assessment in the U.S.

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the U.S. debut of its new cognitive assessment platform IntelliSpace Cognition. Leveraging the power of artificial intelligence (AI) and Philips' cloud-based HealthSuite Digital Platform, IntelliSpace Cognition provides healthcare professionals with a powerful aid for assessing cognitive impairment.

IntelliSpace Cognition automates and enhances well-established neuropsychological tests, offering new insights for clinicians treating patients with debilitating neurological conditions. It provides direct access to detailed information about a patient’s cognition while also providing quantitative longitudinal data to aid in assessing disease progression and treatment efficacy.

"There is a real need for quantitative measures to assess the cognitive impairment of people with neurological disease," said Dr. Joseph Fritz, CEO of DENT Neurologic Institute, the first neurology practice to use IntelliSpace Cognition. "Computerized tools and intelligent algorithms offer new opportunities in this area to improve care. The depth of information now available and the efficiency with which we can perform assessments can be very helpful for providing feedback to patients and families sooner and developing treatment plans more quickly."

"While dealing with the rising tide of neurological disease remains a great challenge, our solution will facilitate robust and reliable cognitive assessment with greater efficiency and scale than traditional methods," said Jeroen Tas, Chief Innovation & Strategy Officer at Philips. "Combining this with imaging-based diagnostics we aim to offer care providers more meaningful insights into the health of their patients and potentially open up new possibilities for treatment in the future."

A crucial care pathway for neurologists is to refer patients to neuropsychologists whose expertise in assessing cognitive issues provides important information for treatment. While treatment may be limited for some neurodegenerative diseases, it is vital to act as early as possible to establish an appropriate care plan or treatment protocol.

The number of neuropsychologists able to perform an assessment is limited and coupled with a rise in the number of patients suffering from neurological conditions, there is a need for new innovative solutions. A rapid and reliable method for neurologists to better assess cognition and select those that would benefit from seeing a neuropsychologist would alleviate pressure on this part of the healthcare system. Results from a study conducted by Philips support interest in new solutions to address these issues. Ninety-two percent of neurologists indicated that the IntelliSpace Cognition concept would be appealing to use within their practice [1].

Philips has invested in collecting insights from both neurologists and neuropsychologists in order to design IntelliSpace Cognition in an iterative manner and ensure it fits into the majority of existing workflows. IntelliSpace Cognition was developed under a quality management system for medical devices and has undergone rigorous usability testing and a monitored clinical trial has been performed to validate the digital cognitive tests and collect normative data from healthy individuals that reflect the U.S. population. The Philips study found that 80% of neurologists said they would feel confident using IntelliSpace Cognition because Philips has collected normative data to provide peer comparisons to a healthy group.

In the typical workflow, illustrated in this video, a patient performs various tests on a tablet under minimal supervision of an assistant with audio prompts to guide in tasks such as drawing a clock, joining numbered dots or remembering a sequence of numbers. The results of the tests are then communicated to IntelliSpace Cognition's cloud-based computing platform, where advanced validated algorithms perform analytics to present the clinician with the results. IntelliSpace Cognition is just one part of an expanding neurology IT portfolio of Philips which includes, neuroimaging, high density EEG and now digital cognitive assessment.

IntelliSpace Cognition will initially be commercially available only in the U.S.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 80,000 employees with sales and services in more than 100 countries.

1. Based on a 2019 Philips study of 100 neurologists in the U.S.

Most Popular Now

Open Call SC1-DTH-12-2020: Use of Real-W…

The number of people with chronic illness is growing and almost half of them have multiple chronic conditions. Patients with complex chronic conditions (CCCs) have chronic multi-morbidities or chronic disease...

China to Take on Leading Role in Medical…

Asia, in particular China, has been advancing significantly on its way to a key role in geopolitics, says correspondent Frank Sieren - and towards spearheading developments in medical technologies. At...

Doctors Give Electronic Health Records a…

The transition to electronic health records (EHRs) was supposed to improve the quality and efficiency of healthcare for doctors and patients alike - but these technologies get an "F" rating...

Artificial Intelligence Algorithm can Le…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of researchers at the University of...

Preventive Health Care Via App

Demand for apps for preventive health care is growing all the time. Particularly popular are diagnostic assistants that record physiological and fitness data. However, there are data protection concerns with...

Bittium Exhibits its Innovative High-Tec…

Bittium exhibits its innovative products and solutions for cardiology and neurology at Medica 2019, the leading international trade fair for the medical sector, on November 18 - 21 in Dusseldorf...

Artificial Intelligence-Based Algorithm …

Traumatic brain injury (TBI) is a significant global cause of mortality and morbidity with an increasing incidence, especially in low-and-middle income countries. The most severe TBIs are treated in intensive...

MEDICA 2019 + COMPAMED 2019 Due to Launc…

18 - 21 November 2019, Düsseldorf, Germany. From Monday until Thursday, the entire medical world and health care sector will once again meet in Düsseldorf. With a record participation of a...

A Mobile App for Managing Mobile Medical…

Beginning of March 2019, Merci Charity Boutique association based in Bucharest, Romania started testing the "Mobile app for mobile medical units and cabinets", which helps the mobile dental practice to...

#FH2019 - The Leading International Conf…

13 - 15 November 2019, Berlin, Germany. This year the German capital will host again the main conference dedicated to Digital Health: Frontiers Health 2019, which will be held from the...

MEDICA and COMPAMED Hold their Own in a …

18 - 21 November 2019, Düsseldorf, Germany. The demand market for medical technology and medical products is becoming increasingly challenging and discriminating worldwide. Providers are adapting to this on a flexible...

GE Healthcare Expands Intelligent Health…

GE Healthcare launched the Edison Developer Program to accelerate the adoption and impact of intelligent applications and developer services across health systems. The program is based on Edison, GE Healthcare's...